QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Insulin Glargine History, Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Insulin Glargine: History, Classification, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient reports persistent swelling and a firm mass at a repeatedly used injection site with unstable glucose control. What is the most appropriate next pharmacovigilance assessment?

Assume the lesion is ordinary lipohypertrophy and close the report Consider lipohypertrophy and localized cutaneous amyloidosis, document lesion characteristics and assess absorption changes after site rotation Classify it immediately as systemic anaphylaxis Conclude that the insulin has lost receptor activity

Question 2 of 10 Which statement best describes the relationship between insulin glargine's long duration and its receptor activity?

Long duration results because the receptor remains continuously activated by an irreversibly bound molecule Long duration is primarily determined by depot-controlled absorption, while absorbed molecules produce conventional insulin-receptor signalling Long duration results exclusively from hepatic metabolism of insulin glargine The insulin receptor is not involved in the basal effect

Question 3 of 10 Which approach is most appropriate when assessing hypoglycaemia seriousness?

Classify seriousness solely from the lowest glucose value Use regulatory seriousness criteria, considering consequences such as hospitalisation, seizure, coma or need for assistance Classify every glucose value below a fixed threshold as serious Classify the event as non-serious if glucose normalized after oral carbohydrate

Question 4 of 10 Which statement best describes insulin glargine's therapeutic role in type 1 diabetes?

It normally replaces the meal-related insulin bolus and eliminates the need for prandial insulin It provides basal insulin coverage and is generally used with rapid- or short-acting insulin for meals and corrections It is primarily used as an intravenous insulin for acute ketoacidosis It provides glucose-independent protection against hypoglycaemia

Question 5 of 10 A report alleges that insulin glargine caused vision loss shortly after intensified glycaemic control. What is the most appropriate initial interpretation?

Classify all vision loss as a direct toxic effect of insulin glargine Dismiss the report because improved glycaemic control cannot affect vision Obtain ophthalmic diagnosis and timing to distinguish refractive change, retinopathy progression, macular oedema and unrelated disease Assume the event proves permanent retinal toxicity

Question 6 of 10 Which report contains the most useful minimum information for investigating severe nocturnal hypoglycaemia?

Only the brand name and the patient's age Only the glucose value measured after emergency treatment Exact product and dose, timing, food and exercise, renal function, glucose trajectory, rescue treatment and recurrence Only whether the event occurred at night

Question 7 of 10 Which statement best explains why renal or hepatic impairment may require clinical insulin dose review?

Impairment always increases insulin clearance and therefore requires dose escalation Reduced clearance can lower insulin requirements, but illness, stress and nutrition may move requirements in the opposite direction Organ impairment has no effect on insulin exposure A universal dose formula applies regardless of diabetes type and clinical status

Question 8 of 10 A patient develops recurrent hypoglycaemia after moving injections from a lipohypertrophic area to normal subcutaneous tissue. Which mechanism is most plausible?

Normal tissue may absorb insulin more effectively, increasing effective exposure Lipohypertrophic tissue always increases insulin absorption The insulin receptor becomes permanently hypersensitive after site rotation Changing sites chemically converts U100 insulin into U300 insulin

Question 9 of 10 Why can intravenous administration of insulin glargine cause severe hypoglycaemia despite its intended long-acting profile?

Intravenous administration bypasses the subcutaneous depot and makes insulin immediately available Intravenous administration converts insulin glargine into a glucagon analogue The insulin receptor is only activated after intravenous administration The acidic formulation becomes more stable in the bloodstream and accumulates indefinitely

Question 10 of 10 Which data strategy is most appropriate for detecting a batch-related insulin device or potency signal?

Review only the total number of reports for all insulin products combined Stratify complaints by batch, device model, market, complaint type and time, while retaining physical products where possible Exclude reports lacking confirmed mechanical failure before reviewing them Compare spontaneous-report counts without considering exposure or product identity

QPPV.com

Knowledge Assessment: Insulin Glargine History, Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings